[HTML][HTML] A network meta-analysis of the efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in dialysis chronic kidney disease

J Chen, X Shou, Y Xu, L Jin, C Zhu, X Ye, Z Mei… - Aging (Albany …, 2023 - ncbi.nlm.nih.gov
Background: Five types of HIF-PHIs have been authorized for anemia treatment in CKD
patients in China and Japan. These are enarodustat, roxadustat, daprodustat, vadadustat …

A network meta-analysis of the efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in dialysis chronic kidney disease.

J Chen, X Shou, Y Xu, L Jin, C Zhu, X Ye, Z Mei… - Aging, 2023 - europepmc.org
Background Five types of HIF-PHIs have been authorized for anemia treatment in CKD
patients in China and Japan. These are enarodustat, roxadustat, daprodustat, vadadustat …

A network meta-analysis of the efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in dialysis chronic kidney disease

J Chen, X Shou, Y Xu, L Jin, C Zhu, X Ye, Z Mei… - …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Five types of HIF-PHIs have been authorized for anemia treatment in CKD
patients in China and Japan. These are enarodustat, roxadustat, daprodustat, vadadustat …

A network meta-analysis of the efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in dialysis chronic kidney disease.

J Chen, X Shou, Y Xu, L Jin, C Zhu, X Ye, Z Mei… - Aging, 2023 - europepmc.org
Background Five types of HIF-PHIs have been authorized for anemia treatment in CKD
patients in China and Japan. These are enarodustat, roxadustat, daprodustat, vadadustat …